Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company, announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. The presentation will include a live question-and-answer session, offering investors a direct opportunity to engage with the company's leadership.
The company plans to highlight recent milestones, including the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This progress is a critical step in the clinical development of the drug, which is being evaluated for the treatment of cancer. Additionally, Oncotelic has expanded its European clinical sites, which could accelerate patient enrollment and broaden the geographic scope of its trials.
A key focus of the presentation will be the validation of Oncotelic's Deciparticle platform through peer-reviewed publications. The Deciparticle technology is a proprietary drug delivery system designed to enhance the efficacy and safety of therapeutic agents. Validation in peer-reviewed journals strengthens the scientific credibility of the platform, which is central to the company's nanomedicine approach.
Oncotelic also intends to discuss its scalable cGMP manufacturing capabilities. These capabilities are essential for transitioning from clinical trials to commercial production, ensuring that the company can meet regulatory requirements and supply demands.
Furthermore, the company will highlight its continued development of AI-driven drug discovery, robotics, and nanomedicine platforms. The integration of artificial intelligence into drug discovery has the potential to significantly reduce the time and cost associated with bringing new therapies to market. By leveraging AI, Oncotelic aims to identify promising drug candidates more efficiently and optimize their development.
The presentation at the OTCQB Virtual Investor Conference provides a platform for Oncotelic to communicate its strategic vision and operational progress to the investment community. For leaders in business and technology, this news underscores the growing convergence of biotechnology and artificial intelligence, a trend that is reshaping the pharmaceutical industry.
The implications of Oncotelic's advancements are far-reaching. The progression of the Everolimus trial could offer new treatment options for cancer patients, while the validation of the Deciparticle platform could enhance the delivery of a wide range of therapeutics. Moreover, the company's AI-driven platforms represent a shift toward more data-driven and efficient drug development processes, which could have a transformative impact on the industry.
Investors and stakeholders can access the full press release for more details at https://nnw.fm/fGHUt. Additionally, the latest news and updates regarding Oncotelic are available in the company's newsroom at https://nnw.fm/OTLC.
Oncotelic Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Its portfolio includes clinical-stage oncology assets, proprietary Deciparticle drug delivery technology, AI-enabled drug discovery platforms, and scalable GMP manufacturing capabilities. These integrated technologies are designed to accelerate development while improving patient outcomes.
As the company prepares to present at the conference, the biotech and tech industries will be watching closely to gauge the potential of these emerging technologies. The event could serve as a catalyst for further investment and collaboration in the field of AI-driven drug discovery and nanomedicine.
